Literature DB >> 19757175

The role of lysophosphatidic acid receptors in phenotypic modulation of vascular smooth muscle cells.

Zhibin Zhou1, Jianping Niu, Zhijun Zhang.   

Abstract

Lysophosphatidic acid (LPA) is a bioactive lipid with diverse physiological effects via activation of G protein-coupled receptors (GPCRs). It has been implicated as a specific dedifferentiation factors that can promote phenotypic modulation of cultured vascular smooth muscle cells (VSMCs) which is critically involved in various vascular disease. However, the role of LPA receptors and details of their signaling in LPA induced phenotypic modulation are largely unexplored. In this study we detect the expression of LPA1 and LPA3 in rat aortic smooth muscle cells (RASMCs). LPA promoted RASMCs phenotypic modulation in a dose-dependent manner and coordinated induced the phosphorylation of p38 mitogen-activated protein kinase (p38MAPK) and extracellular signal-regulated kinase (ERK). LPA-induced cell phenotypic modulation was significantly inhibited by specific LPA1/LPA3-receptor antagonist dioctyl-glycerol pyrophosphate (DGPP8:0) at concentration, but this inhibitive effect was lost when the antagonist was coadministered with a highly selective LPA3 agonist,1-oleoyl-2-Omethyl-rac-glycero-phosphothionate (OMPT). In addition, pertussis toxin (PTX), a Gi protein inhibitor had little affect on the LPA-induced phenotypic modulation in RASMC. These data suggest that LPA-induced phenotypic modulation is mediated through the PTX-insensitive G-protein(s), possibly Gq-coupled LPA3 receptor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19757175     DOI: 10.1007/s11033-009-9798-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  43 in total

Review 1.  Vascular smooth muscle growth: autocrine growth mechanisms.

Authors:  B C Berk
Journal:  Physiol Rev       Date:  2001-07       Impact factor: 37.312

Review 2.  The smooth muscle cell in culture.

Authors:  J Chamley-Campbell; G R Campbell; R Ross
Journal:  Physiol Rev       Date:  1979-01       Impact factor: 37.312

Review 3.  Lysophosphatidic acid receptors.

Authors:  J J Contos; I Ishii; J Chun
Journal:  Mol Pharmacol       Date:  2000-12       Impact factor: 4.436

Review 4.  Mechanical, biochemical, and extracellular matrix effects on vascular smooth muscle cell phenotype.

Authors:  Jan P Stegemann; Helen Hong; Robert M Nerem
Journal:  J Appl Physiol (1985)       Date:  2005-06

Review 5.  Smooth muscle cell heterogeneity: patterns of gene expression in vascular smooth muscle cells in vitro and in vivo.

Authors:  C M Shanahan; P L Weissberg
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-03       Impact factor: 8.311

Review 6.  International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Edward J Goetzl; Timothy Hla; Yasuyuki Igarashi; Kevin R Lynch; Wouter Moolenaar; Susan Pyne; Gabor Tigyi
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

7.  Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors.

Authors:  K Bandoh; J Aoki; A Taira; M Tsujimoto; H Arai; K Inoue
Journal:  FEBS Lett       Date:  2000-07-28       Impact factor: 4.124

8.  CArG elements control smooth muscle subtype-specific expression of smooth muscle myosin in vivo.

Authors:  I Manabe; G K Owens
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

9.  Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells.

Authors:  O Fourcade; M F Simon; C Viodé; N Rugani; F Leballe; A Ragab; B Fournié; L Sarda; H Chap
Journal:  Cell       Date:  1995-03-24       Impact factor: 41.582

10.  Vascular remodeling induced by naturally occurring unsaturated lysophosphatidic acid in vivo.

Authors:  Kenji Yoshida; Wataru Nishida; Ken'ichiro Hayashi; Yasuyuki Ohkawa; Akira Ogawa; Junken Aoki; Hiroyuki Arai; Kenji Sobue
Journal:  Circulation       Date:  2003-09-22       Impact factor: 29.690

View more
  7 in total

Review 1.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 2.  An overview of potential molecular mechanisms involved in VSMC phenotypic modulation.

Authors:  Ming-Jie Zhang; Yi Zhou; Lei Chen; Yan-Qin Wang; Xu Wang; Yan Pi; Chang-Yue Gao; Jing-Cheng Li; Li-Li Zhang
Journal:  Histochem Cell Biol       Date:  2015-12-26       Impact factor: 4.304

3.  Tissue factor pathway inhibitor suppresses the growth of human vascular smooth muscle cells through regulating cell cycle.

Authors:  Xia Dong; Liping Song; Dunwan Zhu; Hailing Zhang; Lanxia Liu; Xigang Leng
Journal:  Mol Biol Rep       Date:  2010-12-04       Impact factor: 2.316

4.  Expression of multiple membrane-associated phospholipase A1 beta transcript variants and lysophosphatidic acid receptors in Ewing tumor cells.

Authors:  Benjamin Joachim Schmiedel; Christoph Hutter; Manuela Hesse; Martin Sebastian Staege
Journal:  Mol Biol Rep       Date:  2010-12-04       Impact factor: 2.316

5.  LPA receptor 4 deficiency attenuates experimental atherosclerosis.

Authors:  Liping Yang; Maria Kraemer; Xianjun Frank Fang; Peggi M Angel; Richard R Drake; Andrew J Morris; Susan S Smyth
Journal:  J Lipid Res       Date:  2019-02-22       Impact factor: 5.922

Review 6.  Lysophosphatidic acid in atherosclerotic diseases.

Authors:  Andreas Schober; Wolfgang Siess
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

7.  Lysophosphatidic acid induces integrin activation in vascular smooth muscle and alters arteriolar myogenic vasoconstriction.

Authors:  Marius C Staiculescu; Francisco I Ramirez-Perez; Jorge A Castorena-Gonzalez; Zhongkui Hong; Zhe Sun; Gerald A Meininger; Luis A Martinez-Lemus
Journal:  Front Physiol       Date:  2014-10-31       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.